Eli Lilly reported a strong revenue jump driven by the blockbuster performance of its weight loss and diabetes drugs, ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...

For the last two years, the company's primary source of growth has been the blockbuster drugs Mounjaro and Zepbound. These are Lilly's glucagon-like peptide-1 (GLP-1) medicines, which compete ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... as well as newer medications like Jardiance, Mounjaro, Trulicity, and Zepbound for obesity and type 2 diabetes.

Share on Pinterest Mounjaro helps maintain weight loss at ... Researchers from the University of Padova in Italy, in collaboration with Eli Lilly and Company, have extended findings from the ...

Eli Lilly's "promising" results could hint at the pill being a viable alternative to Novo's Ozempic and even the company's own drugs Zepbound and Mounjaro — but it's still too early to draw any ...

Continue » Lilly's Mounjaro and Zepbound, which share the same generic drug (tirzepatide), are already giving Ozempic and Wegovy, which also share the same generic (semaglutide), a run for their ...

Lilly, which already markets the diabetes drug Mounjaro and the weight-loss treatment Zepbound, said orforglipron matches the safety and tolerability of injectable GLP-1 drugs. Trump’s Health ...

All current obesity treatments - Novo Nordisk’s Ozempic, Wegocy and Saxenda, and Lilly’s Mounjaro - are delivered by weekly injection and there has been a race among the biggest pharma ...

Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Lilly’s growth. While the aforementioned are the safer bets ...